Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts

About Roche Holding

Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions.

What are the underlying business or industry changes driving this perspective?

• Late stage pipeline breadth, including 10 new molecular entities moving into Phase III and the potential launch of up to 19 medicines by the end of the decade, gives Roche multiple shots on goal that can feed new revenue lines and help offset loss of exclusivity impacts on earnings.
• Giredestrant, fenebrutinib, Gazyva kidney indications, CT-388 in obesity and other post bar projects are aligned with long term shifts toward targeted, high impact therapies in oncology, neurology, immunology and metabolic disease, which can support mix quality and core operating margins if they convert to on market franchises.
• Next generation sequencing, the cobas Mass Spec 601 platform, broader neurology and infectious disease assays, and a growing companion diagnostics portfolio position Roche to benefit from rising use of complex diagnostics in clinical decision making, with potential to lift Diagnostics sales growth and core operating profit over time.
• Roche’s agreement with the U.S. government that provides tariff exemptions and commits about US$50b of U.S. R&D and PP&E investment over 5 years improves supply chain visibility and cost planning, which can support net margins and cash generation if execution stays on track.
• Company wide use of AI across R&D and operations, portfolio pruning of high risk low value projects and a stated intent to keep core operating margins at least stable create an internal efficiency push that can help translate mid single digit sales growth into faster core EPS growth.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Roche Holding's revenue will grow by 2.5% annually over the next 3 years.
• Analysts assume that profit margins will increase from 20.3% today to 25.5% in 3 years time.
• Analysts expect earnings to reach CHF 17.4 billion (and earnings per share of CHF 21.72) by about July 2029, up from CHF 12.9 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as CHF19.8 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 18.4x on those 2029 earnings, down from 20.7x today. This future PE is lower than the current PE for the GB Pharmaceuticals industry at 35.8x.
• Analysts expect the number of shares outstanding to decline by 0.09% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 3.94%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• China healthcare pricing reforms are already linked to a 24% sales decline in Diagnostics in that market and a 25% reduction in Core Lab oncology reagents. Any extension of similar pricing pressure to other product categories or regions could cap volume growth and compress Diagnostics core operating margins and group earnings.
• The obesity, CVRM and broader late stage pipeline, including CT-388, CT-868, petrelintide and other NMEs, still faces Phase II and Phase III execution and regulatory risk. Any setbacks or slower than expected adoption versus entrenched competitors could leave Roche more reliant on the existing portfolio, which would weigh on long term revenue growth and future earnings.
• Roche highlights repeated loss of exclusivity impacts of around CHF 1b to CHF 1.5b a year and growing biosimilar and generic pressure on franchises such as Actemra, Xolair, HER2 therapies and future products. If new launches and label expansions for assets like giredestrant, fenebrutinib, Gazyva and Vabysmo do not sufficiently offset this, overall sales growth and net margins could come under pressure.
• Currency movements have already reduced reported growth by 5 percentage points on sales and 8 percentage points on core operating profit and core EPS. Continued weakness in key currencies such as the US dollar versus the Swiss franc could further dilute reported revenue and earnings progress even if the underlying business trends remain positive.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CHF359.22 for Roche Holding based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF428.0, and the most bearish reporting a price target of just CHF230.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF68.3 billion, earnings will come to CHF17.4 billion, and it would be trading on a PE ratio of 18.4x, assuming you use a discount rate of 3.9%.
• Given the current share price of CHF335.5, the analyst price target of CHF359.22 is 6.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.